Specialized to manufacture oral solid dosage forms, Alcami’s Wilmington, North Carolina site supports preclinical production through commercial launch and supply. Our cGMP manufacturing technologies are arranged in flexible suites to support advanced and complex projects.
Due to counterfeiting, adulteration, theft, and diversion, governments and regulatory agencies have developed regulations to enhance patient safety and supply chain security. On November 27, 2013, the Drug Supply Chain Security Act (DSCSA) made effective several additional requirements that impact labeling and data management for commercially distributed prescription human drug product in the United States.
Whether you are looking for an all-inclusive integrated offering or an individualized development or manufacturing service, Alcami has the solution to the complex needs of your product.
The increasing trend of highly potent active pharmaceutical ingredients (HPAPIs) being used in new drug development candidates has created a tremendous demand for high containment development and production capabilities.
Balancing HPAPI Control with the Chemistry and Efficiency Needs of a CDMO
Extractables & Leachables 101: The Past, Present, and Future
The Importance of Microbial In-Use Studies
Early Phase Development of Biologics
The Importance of Secondary Packaging
Editorial: The Changing R&D Landscape
Editorial: How to Find Your Secret Source
Editorial: Considerations for Approval of Biosimilars
eBook: Analytical Testing in Drug Development
500Investigational New Drug (IND) Filings
500,000ft² across US & EU facilities
600 US & EU regulatory filings
Alcami Featured in Wisconsin Biohealth Industry Profile
Alcami Launches New Rapid Sterility Testing Services
Alcami and Wisconsin Department of Natural Resources Enter Third Year of Environmental Stewardship Program
PharmSci 360 - November 4 - 6
CPhI Worldwide - November 5 - 7
Pharma Integrates - November 18 - 19
